Clinical inertia is defined as the failure to establish appropriate targets and escalate treatment to achieve treatment goals. It accounts for a significant proportion of failure to achieve targets in the management of diabetes and contributes to up to 200,000 adverse diabetes-related outcomes per year. of which appears to reduce clinical inertia as evidenced by the ''placebo effect'' of clinical trials. We plan to review here, the lessons that can be learnt from clinical trials and how these may translate to better care for people with diabetes.
INTRODUCTION
Clinical inertia, the failure to establish appropriate targets and escalate treatment to achieve treatment goals, is responsible for substantial preventable complications of diabetes with the associated excess in direct and indirect health care costs. If ''clinical inertia'' was an intervention associated with this increased risk of complications, it would rapidly be withdrawn pending safety analyses.
However, the lack of appropriate escalation of treatment is accepted in every day practice. The concept of clinical inertia is not new. Despite the availability of effective glucose-lowering therapies with low risk of hypoglycaemia and weight gain, there is a persistent failure to achieve the established targets in almost half of people with diabetes.
PREVALENCE OF CLINICAL INERTIA
Clinical inertia is a worldwide phenomenon, particularly when considering initiation of insulin in persons with type 2 diabetes. In the United States, for example, an observational study in 3,891 persons with diabetes registered with a health maintenance organisation reported a delay of almost 3 years in patients with consistently elevated glycosylated haemoglobin (HbA1c) levels despite dual once a day (OAD) therapy (metformin and sulfonylurea) [1, 2] . Further, a multinational, 26-week observational study reported an HbA1c level of 8.9% (74 mmol/mol) at insulin initiation [3] . A Canadian study in adults with diabetes aged C65 years (n = 2,502) found that, although diabetologists are more likely to initiate insulin based on poor glycaemic control (HbA1c [8%), only 45% intensified treatment overall compared with 37% of primary care physicians [1] . Unfortunately, this reluctance influences the patient perceptions of diabetes therapies and may deter them from accepting insulin therapy [1, 4, 5] . The fear of side effects can cause hesitancy to comply with insulin therapy [6] .
Paradoxically, the dialogue prior to insulin initiation often vilifies the therapy itself.
Insulin may also be perceived as a punishment rather than a necessary part of the management of this progressive condition. In doing so, physicians can be the root cause of nonadherence to their own prescriptions [7] .
There is also reluctance to initiate combination therapies in early-stage disease; movement beyond monotherapy in patients who are asymptomatic is often slow, particularly when faced with a lack of confidence or experience with newer therapies.
Once therapy is initiated, there is also a lack of organisational mechanisms to help physicians monitor response to therapy. Guidelines indicate that the benefits, or otherwise, of therapy should be monitored and if target is not achieved, therapy adjusted. This, however, very rarely takes place, particularly with the generic familiar treatments, such as sulphonylureas. In the absence of good mechanisms to monitor response to therapy prior to review, further unnecessary delays often occur prior to any changes in therapy. In these settings, a 'wait until next visit' approach is often adopted, particularly when faced with soft rationalisations by patients to avoid treatment intensification [7] . Yet, the increased awareness and methods of quantification have done little to improve outcomes. Time to intensification of treatment has not significantly improved since 1990s to date [2] . 
THE COST OF CLINICAL INERTIA

CAUSES OF CLINICAL INERTIA
Part of the acceptance of clinical inertia is because there is no single identifiable fault.
Rather, it is a multifactorial condition, with contributory factors from the people with diabetes, the physicians and the system in which they operate.
Physician Factors
Whereas physicians are able to accurately identify clinical inertia in their peers, they consistently overrate the quality of the care they provide. Additionally, they substantially underestimate the number of their own patients that are not at targets. There are three potential points on the pathway to good control where these can fail-setting the appropriate target, initiating appropriate treatment and modifying the treatment in response to outcomes.
Establishing Goals
Physicians tend to set targets based on treatment strategies with which they are most familiar, appropriate for the individual or not.
To date there is only one study which has evaluated the feasibility of individualising treatment targets [9] . Despite being provided clear guidance on how to personalise targets, conventional targets of around 7% were still set, demonstrating inertia of a different sort-the reluctance to move away from conventional targets and therefore potentially overtreat certain individuals. 
Patient Factors Contributing to Clinical Inertia
The causes of clinical inertia do not solely lie with physicians. Non-adherence to lifestyle modifications and prescribed drug treatments is estimated to count up to nearly 100% [11] .
The underlying reasons for this are unclear. and regain driven by an economic crisis in Cuba [12] . In this survey, an average population wide *5.5 kg weight loss was associated with rapid significant declines in diabetes and heart disease prevalence, whereas a weight rebound led to a diabetes prevalence that even exceeded precrisis levels [12] . Patient understanding of, and engagement with, their treatment can be a crucial determinant of adherence [13] as it may be adversely influenced by attitudes, negative media publicity and resultant misperception [14, 15] . 
IN SUMMARY
The 
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